1.81
+0.09(+5.23%)
Currency In USD
Previous Close | 1.72 |
Open | 1.79 |
Day High | 1.9 |
Day Low | 1.77 |
52-Week High | 6.77 |
52-Week Low | 1.15 |
Volume | 8.07M |
Average Volume | 5.65M |
Market Cap | 286.82M |
PE | -3.85 |
EPS | -0.47 |
Moving Average 50 Days | 1.67 |
Moving Average 200 Days | 2.47 |
Change | 0.09 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $187.18 as of October 21, 2025 at a share price of $1.81. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $541.92 as of October 21, 2025 at a share price of $1.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
GlobeNewswire Inc.
Oct 07, 2025 1:00 PM GMT
DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered in
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
GlobeNewswire Inc.
Oct 06, 2025 12:00 PM GMT
- Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esop